The RxView Blog

Real world data, analytics, and insights for healthcare decision makers

Advera Health Analytics, Inc.

Data Is Everything… Or Is It? Why Data Management Matters

Posted by Brian Overstreet on January 7, 2016

On Wednesday, Jan. 6, Forbes ran an article detailing a 7% drop in the price of Regeneron’s (REGN) stock price.  The company attributed that decline to investors obtaining data from the FDA Adverse Events Reporting System (FAERS) showing eight suicide cases from patient’s taking Regeneron’s new PCSK9 inhibitor Praluent (alirocumab).

The issue, of course, was that the people who obtained those data knew nothing about FAERS or its myriad problems with case duplications, incomplete records, or how to value reports submitted with multiple drugs and/or from dubious sources.

Read More

Topics: Big Data, FAERS, FOIA, Praluent, Regeneron, PCSK9

Subscribe to Email Updates